Emerging Company Profile
Triangle: People are the assets
The birth of Triangle Pharmaceuticals Inc. - its "defining moment," as Chairman and CEO David Barry put it - was the Glaxo-Wellcome merger earlier this year.
As a result of the takeover, Wellcome's antiviral group was to be subsumed into the new company, the team was going to be split up, and the Wellcome group's agenda would be subordinated to Glaxo's, said Nick Ellis, Triangle's president and COO.
For a group of senior managers at Wellcome, these unsatisfying circumstances became the driving force to form a new company - Triangle - focused on antiviral and anticancer products capable of evading the drug resistance mechanisms of viruses and tumor cells.